Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 31% in 4 WeeksZacks Investment Research • 12/12/22
Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology MeetingGlobeNewsWire • 12/11/22
Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical TrialGlobeNewsWire • 12/07/22
Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 23.8% in 4 WeeksZacks Investment Research • 11/22/22
Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial ResultsGlobeNewsWire • 11/08/22
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742GlobeNewsWire • 11/08/22
Goldman Sachs Has 5 Stocks to Buy Under $10 With 100% to 800% Upside Potential24/7 Wall Street • 10/29/22
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022GlobeNewsWire • 10/12/22
Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/06/22
Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid LeukemiaGlobeNewsWire • 08/22/22
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AMLPRNewsWire • 08/16/22
Can Kronos Bio, Inc. (KRON) Climb 312% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 08/09/22
Kronos Bio Reports Recent Business Progress and Second-Quarter 2022 Financial ResultsGlobeNewsWire • 08/04/22
Kronos Bio, Inc. (KRON) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 07/08/22
Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 CongressGlobeNewsWire • 06/10/22
Biotech Dominates Goldman Sachs 5 Buy-Rated Stocks Under $10 With 400% to 800% Upside Potential24/7 Wall Street • 05/21/22
Kronos Bio Announces Participation in H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/17/22
Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 CongressGlobeNewsWire • 05/12/22
Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial ResultsGlobeNewsWire • 05/04/22
Goldman Sachs Has 5 Stocks Rated Buy Under $10 With 75% to 500% Upside Potential24/7 Wall Street • 04/15/22
Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACRGlobeNewsWire • 04/08/22
Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With Up to 600% Upside Potential24/7 Wall Street • 03/26/22
Kronos Bio's Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022GlobeNewsWire • 03/08/22
Kronos Bio Announces Participation in Cowen 42nd Annual Health Care ConferenceGlobeNewsWire • 03/01/22